A retrospective study on tolerability and complications of bacillus Calmette-Guérin (BCG) instillations for non-muscle-invasive bladder cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2013; [accessed on 2014 sep 13]. Available from: http://globocan.iarc.fr.
   Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol. 2009;56:247–256.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88:209–216.
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67:1216–1223.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93:485–490.
   PubMed Web of Science ®Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90–95.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non– muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
   PubMed Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69–76.
   PubMed Web of Science ®Google Scholar
• Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001;57:883–888.
   PubMed Web of Science ®Google Scholar
• Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147:596–600.
   PubMed Web of Science ®Google Scholar
• Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, et al. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer. Med J 2014;93:236–254.
   PubMed Web of Science ®Google Scholar
• To U, Kim J, Chia D. Disseminated BCG: complications of intravesical bladder cancer treatment. Case Rep Med. 2014;2014:362845
   PubMedGoogle Scholar
• Marquez-Batalla S, Fraile-Villarejo E, Belhassen-García M, et al. Disseminated infection due to Mycobacterium bovis after intravesical BCG instillation. WJC. 2014;2:301–303.
   Web of Science ®Google Scholar
• Macleod LC, Ngo TC, Gonzalgo ML. Complications of intravesical bacillus Calmette-Guérin. Can Urol Assoc J. 2014;8:540–544.
   Web of Science ®Google Scholar
• van der Meijden APM, Sylvester RJ, Oosterlinck W, et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44:429–434.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129.
   PubMed Web of Science ®Google Scholar
• Resel Folkersma LE, Belon Lopez Tomasetti JA, Isorna Martinez de la Riva S, et al. Complications of endovesical treatment with BCG in a series of 200 patients. Arch Esp Urol. 1999;52:957–965.
   PubMedGoogle Scholar
• Steg A, Leleu C, Debre B, et al. Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol. 1989;16:161–164.
   PubMed Web of Science ®Google Scholar
• González-Del Vecchio M, Ruíz-Serrano MJ, Gijón P, et al. Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital. Diagn Microbiol Infect Dis. 2016;85:338–343.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi M, Kirkels WJ, EORTC Genito-Urinary Tract Cancer Group, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766–773.
   PubMed Web of Science ®Google Scholar
• Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935–939.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden A, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970.
   PubMed Web of Science ®Google Scholar
• Bishr M, Lattouf JB, Latour M, et al. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J. 2014;8:306–310.
   Google Scholar
• Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol. 2008;26:137–140.
   PubMed Web of Science ®Google Scholar